Could a simple shot replace IV drips for Alpha-1 patients?

NCT ID NCT07555483

Recruiting now Disease control Sponsor: Grifols Therapeutics LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 5 times

Summary

This study tests a new way to give Alpha1-Proteinase Inhibitor—a medicine that helps protect the lungs in people with Alpha-1 Antitrypsin Deficiency. Instead of getting it through a vein at a clinic, participants will receive it as a weekly injection under the skin. The trial will compare two different doses of the new shot to the standard IV doses, focusing on how the body processes the drug and whether it is safe. About 40 adults are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Alpha1-Proteinase Inhibitor (human) given under the skin
What this could lead to: If it works, this could offer a more convenient way to take the same medication at home instead of at a clinic.
What could go wrong: This is a small, early-stage study focused on safety and drug levels, not yet on long-term benefits. The new injection method may cause skin reactions or not work as well as the IV version.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency chronic obstructive pulmonary disease hereditary disease lung disorder obstructive lung disease Pathologic Processes pulmonary emphysema respiratory system disorder Subcutaneous Emphysema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPHA 1-ANTITRYPSIN DEFICIENCY

Contacts and locations

Locations

GC2501 Study Site 100
NOT_YET_RECRUITING

Los Angelas, California, 90095, United States
GC2501 Study Site 101
NOT_YET_RECRUITING

Charleston, South Carolina, 29425, United States
GC2501 Study Site 102
NOT_YET_RECRUITING

Phoenix, Arizona, 85032, United States
GC2501 Study Site 103
NOT_YET_RECRUITING

Gainesville, Florida, 32610, United States
GC2501 Study Site 104
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
GC2501 Study Site 105
NOT_YET_RECRUITING

Miami, Florida, 33136, United States
GC2501 Study Site 106
NOT_YET_RECRUITING

Birmingham, Alabama, 35233, United States
GC2501 Study Site 107
NOT_YET_RECRUITING

Scottsdale, Arizona, 85259, United States
GC2501 Study Site 108
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
GC2501 Study Site 109
NOT_YET_RECRUITING

Dallas, Texas, 75390, United States
GC2501 Study Site 150
RECRUITING

Vejle, Denmark
GC2501 Study Site 250
NOT_YET_RECRUITING

Freiburg im Breisgau, Germany
GC2501 Study Site 300
NOT_YET_RECRUITING

Dublin, D09YD60, Ireland
GC2501 Study Site 350
RECRUITING

Leiden, Netherlands
GC2501 Study Site 400
NOT_YET_RECRUITING

Warsaw, Poland
GC2501 Study Site 450
RECRUITING

Guimarães, Portugal
GC2501 Study Site 451
RECRUITING

Loures, Portugal
GC2501 Study Site 500
RECRUITING

Vigo, Spain
GC2501 Study Site 501
NOT_YET_RECRUITING

Madrid, Spain
GC2501 Study Site 502
NOT_YET_RECRUITING

San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
GC2501 Study Site 503
RECRUITING

Seville, Spain
GC2501 Study Site 550
RECRUITING

Malmö, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.